ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
괴사성 근막염 시장 규모는 최근 현저한 성장을 보이고 있습니다. 2024년 10억 7,000만 달러에서 2025년에는 11억 7,000만 달러에 달하고, CAGR 9.6%로 확대될 전망입니다. 과거의 성장은 세균 감염증 증가, 조기 진단에 대한 의식 증가, 면역 결핍 환자 증가, 세계적인 수술 확대, 의료비 지출 증가 등이 요인으로 예상됩니다.
괴사성 근막염 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 16억 7,000만 달러에 이르고 CAGR은 9.2%를 나타낼 전망입니다. 예측기간의 성장은 만성신장병의 발생률 상승, 감염관리연구에 대한 투자 확대, 신속진단기술의 보급 확대, 신흥 시장에서의 의료시설의 확충, 예방의료대책에 대한 주력 강화 등이 요인으로 에상됩니다. 예측 기간에 예상되는 주요 동향으로는 진단 영상 기술의 진보, 항균 요법의 혁신, 상처 치료 관리 시스템의 개발, 외과적 개입에 관한 연구 개발 및 진전, 원격 의료 및 원격 모니터링의 진보 등이 있습니다.
박테리아 감염의 발생률 증가는 향후 수년간 괴사성 근막염 시장의 성장을 가속할 것으로 예측됩니다. 세균 감염증은 유해한 세균이 체내에 침입, 증식하여 조직 손상이나 질환을 일으키는 병태입니다. 세균 감염증 증가는 주로 항생제에 대한 내성에 의해 발생하며 표준 치료의 효능을 저하시켜 감염의 지속 및 확산을 허용합니다. 이 환경 하에서는 심각한 연부 조직 감염증의 위험성이 높아지고, 기회 병원체가 숙주의 방어 기능을 저하시켜 근막간층에 침입하기 때문에 괴사성 근막염의 확산과 빠른 진행을 직접적으로 초래합니다. 예를 들어 미국 정부기관인 질병관리예방센터(CDC)에 따르면 2024년 3월 결핵증례 수는 2022년 8,320건에서 2023년 9,615건으로 1,295건 증가했습니다. 따라서, 박테리아 감염의 발생률 상승이 괴사성 근막염 시장의 성장을 가속하고 있습니다.
괴사성 근막염 시장의 성장은 의료 지출 증가에 의해서도 뒷받침되고 있습니다. 건강 관리 지출은 정부, 민간 보험 회사, 기업 및 개인이 의료 서비스, 치료, 의약품 및 관련 건강 활동에 할당하는 총 자금을 의미합니다. 장기 관리와 지속적인 치료 개입이 필요한 만성 질환의 유병률 증가로 인해 지출은 증가하는 추세에 있습니다. 건강 관리 증가는 고급 진단 기술, 혁신적인 치료법 및 전문 의료에 대한 접근성을 향상시켜 괴사성 근막염 관리를 개선합니다. 예를 들어 2025년 6월 미국 정부기관인 메디케어 메디케이드 서비스센터(CMS)에 따르면 2023년 국내 의료 부문은 7.5% 증가하여 4조 9,000억 달러에 이르렀고, 1인당 평균 1만 4,570달러로 GDP의 17.6%를 차지했습니다. 메디케어 지출은 8.1% 증가하여 1조 298억 달러에 이르렀고 전국 건강 관리 지출 총액의 21%를 차지했습니다. 따라서 의료비 증가가 괴사성 근막염 시장의 성장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 괴사성 근막염 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 괴사성 근막염 시장 : 성장률 분석
세계의 괴사성 근막염 시장 실적 : 규모와 성장(2019-2024년)
세계의 괴사성 근막염 시장 예측 : 규모와 성장(2024-2029년, 2034F)
세계의 괴사성 근막염 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 괴사성 근막염 시장 치료 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
외과적 죽은 조직 제거술
항생제 요법
고압 산소 요법
기타 치료 유형
세계의 괴사성 근막염 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
유형 I
유형 II
유형 III
세계의 괴사성 근막염 시장 : 연령층별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
소아
성인
노인
세계의 괴사성 근막염 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
병원 약국
소매 약국
온라인 약국
세계의 괴사성 근막염 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
병원
전문 클리닉
응급 의료 센터
가정 의료 서비스 제공업체
제약기업
세계의 괴사성 근막염 시장 세분화 : 외과적 죽은 조직 제거술, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
조기 죽은 조직 제거술
근치 죽은 조직 제거술
연속 죽은 조직 제거술
근막절개술
세계의 괴사성 근막염 시장 세분화 : 항생제 요법, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
정맥내 항생제
경구 항생제
병용 요법
표적 요법
세계의 괴사성 근막염 시장 세분화 : 고압 산소 요법, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
모노플레이스 챔버 요법
멀티플레이스 챔버 요법
보조 요법
수술 후 요법
세계의 괴사성 근막염 시장 세분화 : 기타 치료 유형, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
면역글로불린 요법
지지 요법
상처 치료 관리
통증 관리
제7장 지역별 및 국가별 분석
세계의 괴사성 근막염 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
세계의 괴사성 근막염 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
괴사성 근막염 시장 : 경쟁 구도
괴사성 근막염 시장 : 기업 프로파일
GlaxoSmithKline Public Limited Company : 개요, 제품 및 서비스, 전략 및 재무 분석
Gilead Sciences Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Teva Pharmaceutical Industries Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck And Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
bioMerieux SA : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Cipla Limited
Dr. Reddy's Laboratories Limited
Hikma Pharmaceuticals PLC
Mankind Pharma Limited
Wockhardt Limited
Xellia Pharmaceuticals ApS
Basilea Pharmaceutica International Ltd.
MedGenome Labs Limited
Avita Medical Inc.
HiMedia Laboratories Pvt. Ltd.
CutisCare Pvt. Ltd.
NovaBay Pharmaceuticals Inc.
TCS Biosciences Ltd.
3i Diagnostics Limited
Antabio SA
제32장 세계 시장의 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
괴사성 근막염 시장(2029년) : 새로운 기회를 제공하는 국가
괴사성 근막염 시장(2029년) : 새로운 기회를 제공하는 부문
괴사성 근막염 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Necrotizing fasciitis is a rare but severe, rapidly progressing bacterial infection that leads to extensive destruction of the skin, subcutaneous fat, and fascia-the connective tissue surrounding muscles. This life-threatening condition is most often caused by highly virulent bacteria such as Streptococcus pyogenes or Staphylococcus aureus and is commonly known as a flesh-eating disease. Prompt diagnosis and immediate medical intervention are vital for survival and typically involve broad-spectrum intravenous antibiotics, aggressive surgical debridement, and, in severe cases, intensive supportive care to address systemic complications such as sepsis and multiorgan failure.
The main treatment types for necrotizing fasciitis include surgical debridement, antibiotic therapy, hyperbaric oxygen therapy, and other treatment modalities. Surgical debridement is the medical procedure in which dead, infected, or damaged tissue is removed to halt the spread of the infection and promote healing. The disease is categorized into types I, II, and III and affects various age groups, including pediatric, adult, and geriatric patients. Treatments are provided through multiple distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by various end users, including hospitals, specialized clinics, emergency care centers, home healthcare providers, and pharmaceutical companies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The necrotizing fasciitis market research report is one of a series of new reports from The Business Research Company that provides necrotizing fasciitis market statistics, including necrotizing fasciitis industry global market size, regional shares, competitors with a necrotizing fasciitis market share, detailed necrotizing fasciitis market segments, market trends and opportunities, and any further data you may need to thrive in the necrotizing fasciitis industry. This necrotizing fasciitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The necrotizing fasciitis market size has grown strongly in recent years. It will grow from $1.07 billion in 2024 to $1.17 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. Growth during the historic period can be attributed to the increasing prevalence of bacterial infections, greater awareness of early diagnosis, a rising number of immunocompromised patients, the global expansion of surgical procedures, and increasing healthcare expenditure.
The necrotizing fasciitis market size is expected to see strong growth in the next few years. It will grow to $1.67 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. Growth in the forecast period can be attributed to rising incidences of chronic kidney disease, growing investment in infection control research, increasing adoption of rapid diagnostic technologies, expansion of healthcare facilities in emerging markets, and a stronger focus on preventive healthcare measures. Major trends expected in the forecast period include technological advancements in diagnostic imaging, innovations in antimicrobial therapies, developments in wound care management systems, research and progress in surgical interventions, and advancements in telemedicine and remote monitoring.
The increasing incidence of bacterial infections is expected to drive the growth of the necrotizing fasciitis market in the coming years. Bacterial infections are diseases caused by harmful bacteria invading and multiplying within the body, leading to tissue damage and illness. The rise in bacterial infections is primarily due to antibiotic resistance, which reduces the effectiveness of standard treatments and allows infections to persist and spread. This environment increases the risk of severe soft tissue infections, directly supporting the prevalence and rapid progression of necrotizing fasciitis as opportunistic pathogens exploit weakened host defenses to invade fascial planes. For example, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 cases. Consequently, the increasing incidence of bacterial infections is fueling growth in the necrotizing fasciitis market.
The growth of the necrotizing fasciitis market is also supported by rising healthcare expenditure. Healthcare expenditure refers to the total financial resources allocated by governments, private insurers, businesses, and individuals toward medical services, treatments, medications, and related health activities. Spending is increasing due to the growing prevalence of chronic diseases, which require long-term management and continuous therapeutic interventions. Higher healthcare expenditure improves the management of necrotizing fasciitis by enhancing access to advanced diagnostics, innovative therapies, and specialized care. For instance, in June 2025, according to the Centers for Medicare & Medicaid Services, a US-based government agency, national health expenditures in 2023 rose by 7.5 percent to $4.9 trillion, averaging $14,570 per person and representing 17.6 percent of GDP. Medicare spending increased by 8.1 percent to $1,029.8 billion, accounting for 21 percent of total national health expenditures. Therefore, rising healthcare expenditure is driving growth in the necrotizing fasciitis market.
Major companies in the necrotizing fasciitis market are focusing on innovative therapies, including antibiotics and immunotherapies, to improve infection management and chronic wound care. Antibiotics kill or inhibit bacterial growth, while immunotherapies enhance or modify the body's immune response to fight infections and diseases. For example, in March 2025, Altru Health System, a US-based nonprofit physician-led healthcare organization, launched Hyperbaric Oxygen Therapy (HBO) to support wound healing in patients with chronic or difficult-to-heal conditions. The therapy delivers 100 percent oxygen in a pressurized chamber, improving tissue oxygenation and promoting the body's natural healing processes. It is used to treat conditions such as diabetic foot ulcers, radiation-induced tissue damage, compromised skin grafts, and severe infections, offering a non-invasive adjunct to conventional medical care.
Major companies operating in the necrotizing fasciitis market are GlaxoSmithKline Public Limited Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Limited, Merck And Co. Inc., bioMerieux S.A., Cipla Limited, Dr. Reddy's Laboratories Limited, Hikma Pharmaceuticals PLC, Mankind Pharma Limited, Wockhardt Limited, Xellia Pharmaceuticals ApS, Basilea Pharmaceutica International Ltd., MedGenome Labs Limited, Avita Medical Inc., HiMedia Laboratories Pvt. Ltd., CutisCare Pvt. Ltd., NovaBay Pharmaceuticals Inc., TCS Biosciences Ltd., 3i Diagnostics Limited, Antabio S.A.
North America was the largest region in the necrotizing fasciitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in necrotizing fasciitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the necrotizing fasciitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The necrotizing fasciitis market includes revenues earned by entities through diagnosis and laboratory testing services, surgical and debridement services, antibiotic and drug therapy management, wound care and infection control services, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Necrotizing Fasciitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on necrotizing fasciitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for necrotizing fasciitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The necrotizing fasciitis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment Type: Surgical Debridement; Antibiotic Therapy; Hyperbaric Oxygen Therapy; Other Treatment Type
2) By Type: Type I; Type II; Type III
3) By Age Group: Pediatric; Adult; Geriatric
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Specialized Clinics; Emergency Care Centers; Home Healthcare Providers; Pharmaceutical Companies
Subsegments:
1) By Surgical Debridement: Early Debridement; Radical Debridement; Serial Debridement; Fasciotomy
3. Necrotizing Fasciitis Market Trends And Strategies
4. Necrotizing Fasciitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Necrotizing Fasciitis Growth Analysis And Strategic Analysis Framework
5.1. Global Necrotizing Fasciitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Necrotizing Fasciitis Market Growth Rate Analysis
5.4. Global Necrotizing Fasciitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Necrotizing Fasciitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Necrotizing Fasciitis Total Addressable Market (TAM)
6. Necrotizing Fasciitis Market Segmentation
6.1. Global Necrotizing Fasciitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgical Debridement
Antibiotic Therapy
Hyperbaric Oxygen Therapy
Other Treatment Type
6.2. Global Necrotizing Fasciitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Type I
Type II
Type III
6.3. Global Necrotizing Fasciitis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric
Adult
Geriatric
6.4. Global Necrotizing Fasciitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Necrotizing Fasciitis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialized Clinics
Emergency Care Centers
Home Healthcare Providers
Pharmaceutical Companies
6.6. Global Necrotizing Fasciitis Market, Sub-Segmentation Of Surgical Debridement, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early Debridement
Radical Debridement
Serial Debridement
Fasciotomy
6.7. Global Necrotizing Fasciitis Market, Sub-Segmentation Of Antibiotic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous Antibiotics
Oral Antibiotics
Combination Therapy
Targeted Therapy
6.8. Global Necrotizing Fasciitis Market, Sub-Segmentation Of Hyperbaric Oxygen Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoplace Chamber Therapy
Multiplace Chamber Therapy
Adjunctive Therapy
Postoperative Therapy
6.9. Global Necrotizing Fasciitis Market, Sub-Segmentation Of Other Treatment Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunoglobulin Therapy
Supportive Care
Wound Care Management
Pain Management
7. Necrotizing Fasciitis Market Regional And Country Analysis
7.1. Global Necrotizing Fasciitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Necrotizing Fasciitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
